Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Cladribine Combined with Idarubicin and Ara-C (CLIA) As a Frontline and Salvage Treatment for Young Patients (≤65 yrs) with Acute Myeloid Leukemia

Blood (2016) 128 (22): 1639.

https://doi.org/10.1182/blood.V128.22.1639.1639

Published: 2016

Journal Articles

Early Achievement of MRD-Negativity in IGHV-M utated ( IGHV-M ) Patients Portends Highly Favorable Outcomes after First-Line Treatment of CLL with Fludarabine, Cyclophosphamide and Rituximab (FCR). Serial Monitoring for Minimal Residual Disease (MRD) in Blood after Achieving MRD-Negativity Predicts Subsequent Clinical Relapse

Philip A Thompson, MBBS, Paolo Strati, MD, Michael Keating, MBBS, Susan M. O'Brien, MD, Alessandra Ferrajoli, MD, Jan A Burger, MD PhD, Jeffrey L. Jorgensen, MD PhD, Stefan Faderl, MD, Zeev Estrov, MD, Nitin Jain, MD, Tapan Kadia, MD, Gautam Borthakur, MBBS, Courtney D. DiNardo, MD MSCE, Naval G. Daver, MD, Elias J. Jabbour, MD, William G Wierda, MD PhD

Blood (2016) 128 (22): 232.

https://doi.org/10.1182/blood.V128.22.232.232

Published: 2016

Journal Articles

Methotrexate Clearance in Adult Patients with B-Precursor Acute Lymphoblastic Leukemia Treated with the Mini-Hyper-CVD Regimen

Yogin B Patel, PharmD, Kelsey N Voit, PA, Koji Sasaki, MD, Farhad Ravandi, MD, Deborah A Thomas, MD, Susan M. O'Brien, MD, Gautam Borthakur, MBBS, Guillermo Garcia-Manero, MD, Jorge E. Cortes, MD, Marina Konopleva, MD PhD, Nitin Jain, MD, Maro Ohanian, DO, Rebecca Garris, MS, Jovitta Jacob, RN, Hagop M. Kantarjian, MD, Elias J. Jabbour, MD

Blood (2016) 128 (22): 5194.

https://doi.org/10.1182/blood.V128.22.5194.5194

Published: 2016

Journal Articles

Fludarabine and Cytarabine Based Induction Therapy Is Associated With High Response Rate and Durable Remission With Low Treatment Related Mortality In Elderly Patients With Core-Binding Factor AML (CBF-AML)

Koichi Takahashi, MD, Guillermo Garcia-Manero, MD, Jorge Cortes, MD, Farhad Ravandi, MBBS, Stefan Faderl, MD, Susan O'Brien, MD, Hagop M Kantarjian, MD, Gautam Borthakur, MBBS

Blood (2013) 122 (21): 3945.

https://doi.org/10.1182/blood.V122.21.3945.3945

Published: 2013

Journal Articles

Combination Chemotherapy With Tyrosine Kinase Inhibitors Can Overcome Bcr-Abl Mutations In Acute Lymphoblastic Leukemia Or Blast Crisis CML

Ohad Benjamini, MD, Hagop M Kantarjian, MD, Susan O'Brien, MD, Deborah Thomas, MD, Farhad Ravandi, MD, Preetesh Jain, MD, DM, PhD, Sherry Pierce, Gautam Borthakur, MBBS, Tapan M. Kadia, MD, Elias Jabbour, MD, Zeev Estrov, MD, Rajyalakshmi Luthra, Ph.D., Jorge E. Cortes, MD

Blood (2013) 122 (21): 2734.

https://doi.org/10.1182/blood.V122.21.2734.2734

Published: 2013

Journal Articles

Adverse Prognosis Of Extramedullary Disease In Patients With Chronic Myeloid Leukemia (CML) In The Tyrosine Kinase Inhibitor (TKI) Era: a Cohort Study Of 283 Blastic Phase CML Patients

Young Kwang Chae, MD, MPH, Hagop M Kantarjian, MD, Muhamed Baljevic, MD, Alfonso Quintás-Cardama, MD, Gautam Borthakur, MBBS, Tapan M. Kadia, MD, Susan O'Brien, MD, Carlos G. Romo, M.D., Sherry R. Pierce, RN, BS, Elias Jabbour, Jorge E. Cortes, MD

Blood (2013) 122 (21): 2724.

https://doi.org/10.1182/blood.V122.21.2724.2724

Published: 2013

Journal Articles

Survival Outcomes In Relapsed/Refractory Acute Myeloid Leukemia Patients Who Achieve Less-Than-Complete Response After Salvage Therapy

Shilpan S. Shah, MD, Hagop M Kantarjian, MD, Farhad Ravandi, MBBS, Susan O'Brien, MD, Guillermo Garcia-Manero, MD, Michael Andreeff, MD, PhD, Marina Konopleva, MD, PhD, Elias Jabbour, MD, Sherry R. Pierce, RN, BS, Gautam Borthakur, MBBS, Jorge E. Cortes, MD

Blood (2013) 122 (21): 2654.

https://doi.org/10.1182/blood.V122.21.2654.2654

Published: 2013

Journal Articles

A Phase II Expansion Study Of Vorinostat In Combination With Idarubicin and Cytarabine For Patients With Acute Myelogenous Leukemia (AML) With FLT3 Molecular Alterations

Koichi Takahashi, MD, Elias Jabbour, MD, Farhad Ravandi, MBBS, Gautam Borthakur, MBBS, Jorge E. Cortes, MD, Tapan Kadia, Susan O'Brien, MD, Deborah A. Thomas, MD, Stefan Faderl, MD, Joyce Bass, RN, William G. Wierda, MD, PhD, Naval Daver, MD, Courtney D. DiNardo, MD, Sherry Pierce, Mark Brandt, Hagop M Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2013) 122 (21): 2684.

https://doi.org/10.1182/blood.V122.21.2684.2684

Published: 2013

Journal Articles

Estimated Glomerular Filtration Rate Changes In Patients (Pts) With Chronic Myeloid Leukemia (CML) Treated With Tyrosine Kinase Inhibitors (TKI)

Musa Yilmaz, MD, Hagop M. Kantarjian, MD, Alfonso Quintas-Cardama, MD, Susan O'Brien, MD, Jan A. Burger, MD, PhD, Alessandra Ferrajoli, MD, Gautam Borthakur, MBBS, Farhad Ravandi, MD, Sherry Pierce, Elias Jabbour, MD, Jorge E. Cortes, MD

Blood (2013) 122 (21): 1488.

https://doi.org/10.1182/blood.V122.21.1488.1488

Published: 2013

Journal Articles

Augmented Berlin-Frankfurt-Muenster Based Therapy For Young Adults With Acute Lymphoblastic Leukemia (ALL)

Michael E. Rytting, MD, Deborah A. Thomas, MD, Susan O'Brien, MD, Kurt Schroeder, RN, Rebecca Garris, BSc, Jorge E. Cortes, MD, Farhad Ravandi, MD, Naveen Pemmaraju, MD, Naval Daver, MD, Stefan H. Faderl, MD, Anna R. K. Franklin, MD, Gautam Borthakur, MBBS, Steven M. Kornblau, MD, Hagop M. Kantarjian, MD

Blood (2013) 122 (21): 1400.

https://doi.org/10.1182/blood.V122.21.1400.1400

Published: 2013

Journal Articles

Validation of the Serial Use of the Myelofibrosis Symptom Assessment Form (MF-SAF) for Measuring Symptomatic Improvement: Performance in 86 Myelofibrosis Patients On INCB018424 Clinical Trial.

Ruben A. Mesa, MD, Hagop Kantarjian, Ayalew Tefferi, MD, Richard Levy, MD, Kris Vaddi, Susan Erickson-Viitanen, PhD, Deborah A. Thomas, MD, Jorge Cortes-Franco, MD, Gautam Borthakur, MBBS, Animesh D. Pardanani, MBBS, PhD, Zeev Estrov, MD, Srdan Verstovsek, MD, PhD

Blood (2009) 114 (22): 3917.

https://doi.org/10.1182/blood.V114.22.3917.3917

Published: 2009

Journal Articles

Outcome after Frontline Therapy with the Modified Hyper-CVAD Regimen with or without Rituximab for De Novo Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL).

Deborah A. Thomas, MD, Hagop Kantarjian, MD, Stefan Faderl, MD, William G. Wierda, M.D., Ph.D, Alessandra Ferrajoli, MD, Jan A. Burger, MD, PhD, Jorge Cortes, MD, Charles A. Koller, MD, Gautam Borthakur, MBBS, Zeev Estrov, Marina Konopleva, MD, PhD, Farhad Ravandi, MBBS, Guillermo Garcia- Manero, MD, Susan O’Brien, M.D.

Blood (2008) 112 (11): 1931.

https://doi.org/10.1182/blood.V112.11.1931.1931

Published: 2008

NARROW

Cladribine Combined with Idarubicin and Ara-C (CLIA) As a Frontline and Salvage Treatment for Young Patients (≤65 yrs) with Acute Myeloid Leukemia

Methotrexate Clearance in Adult Patients with B-Precursor Acute Lymphoblastic Leukemia Treated with the Mini-Hyper-CVD Regimen

Fludarabine and Cytarabine Based Induction Therapy Is Associated With High Response Rate and Durable Remission With Low Treatment Related Mortality In Elderly Patients With Core-Binding Factor AML (CBF-AML)

Combination Chemotherapy With Tyrosine Kinase Inhibitors Can Overcome Bcr-Abl Mutations In Acute Lymphoblastic Leukemia Or Blast Crisis CML

Adverse Prognosis Of Extramedullary Disease In Patients With Chronic Myeloid Leukemia (CML) In The Tyrosine Kinase Inhibitor (TKI) Era: a Cohort Study Of 283 Blastic Phase CML Patients

Survival Outcomes In Relapsed/Refractory Acute Myeloid Leukemia Patients Who Achieve Less-Than-Complete Response After Salvage Therapy

A Phase II Expansion Study Of Vorinostat In Combination With Idarubicin and Cytarabine For Patients With Acute Myelogenous Leukemia (AML) With FLT3 Molecular Alterations

Estimated Glomerular Filtration Rate Changes In Patients (Pts) With Chronic Myeloid Leukemia (CML) Treated With Tyrosine Kinase Inhibitors (TKI)

Augmented Berlin-Frankfurt-Muenster Based Therapy For Young Adults With Acute Lymphoblastic Leukemia (ALL)

Validation of the Serial Use of the Myelofibrosis Symptom Assessment Form (MF-SAF) for Measuring Symptomatic Improvement: Performance in 86 Myelofibrosis Patients On INCB018424 Clinical Trial.

Outcome after Frontline Therapy with the Modified Hyper-CVAD Regimen with or without Rituximab for De Novo Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only